Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT00346645 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Phase II Study of Velcade® in Patients Stage IIIB OR IV Non-Small Cell Lung Cancer

StatusTerminated
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Study Status, Sponsor/Collaborators, Referencesv5
  2. Re-verified, no change to tracked fieldsv4
  3. Trial status: Recruiting to Terminated Sponsor's reason: stopped after planned interim analysis for lack of efficacy
    • Primary completion date: May 2007
    • Study completion date: Dec 2007
    • Site details revised
    v3
  4. Study description expanded, about 262 wordsv2
  5. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The purpose of this study is to determine whether Bortezomib is effective in the treatment of patients with non-small-cell lung cancer who have not received any prior chemotherapy regimen for advanced disease.
Trial Details
NCT Number NCT00346645
Lead Sponsor Gustave Roussy, Cancer Campus, Grand Paris
Conditions
(from sponsor)		 STAGE IIIB OR IV NON-SMALL CELL LUNG CANCER
Enrollment 46 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov